Study of REGN2810 in Adults With Cervical Cancer
Status: | Recruiting |
---|---|
Conditions: | Women's Studies |
Therapuetic Areas: | Reproductive |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 8/17/2018 |
Start Date: | October 31, 2017 |
End Date: | June 7, 2023 |
Contact: | Clinical Trials Administrator |
Email: | clinicaltrials@regeneron.com |
Phone: | 844-734-6643 |
An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Therapy of Investigator's Choice Chemotherapy in Recurrent or Metastatic Platinum-Refractory Cervical Carcinoma
The primary objective is to compare overall survival (OS) for patients with recurrent or
metastatic platinum-refractory cervical cancer treated with either REGN2810 or investigator's
choice (IC) chemotherapy.
The secondary objectives are:
- To compare progression-free survival (PFS) of REGN2810 versus IC chemotherapy
- To compare overall response rate (ORR) (partial response [PR] + complete response [CR])
of REGN2810 versus IC chemotherapy per Response Evaluation Criteria in Solid Tumors 1.1
- To compare the duration of response (DOR) of REGN2810 versus IC chemotherapy
- To compare the safety profiles of REGN2810 versus IC chemotherapy by describing adverse
events (AE)
- To compare quality of life (QOL) for patients treated with REGN2810 versus IC
chemotherapy using the European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
metastatic platinum-refractory cervical cancer treated with either REGN2810 or investigator's
choice (IC) chemotherapy.
The secondary objectives are:
- To compare progression-free survival (PFS) of REGN2810 versus IC chemotherapy
- To compare overall response rate (ORR) (partial response [PR] + complete response [CR])
of REGN2810 versus IC chemotherapy per Response Evaluation Criteria in Solid Tumors 1.1
- To compare the duration of response (DOR) of REGN2810 versus IC chemotherapy
- To compare the safety profiles of REGN2810 versus IC chemotherapy by describing adverse
events (AE)
- To compare quality of life (QOL) for patients treated with REGN2810 versus IC
chemotherapy using the European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
The criteria listed below are not intended to contain all considerations relevant to a
patient's potential participation in this clinical trial.
Key Inclusion Criteria:
1. Recurrent, persistent, and/or metastatic cervical cancer, for which there is not a
curative intent option (surgery or radiation therapy with or without chemotherapy).
Acceptable histologies are squamous carcinoma, adenocarcinoma, and adenosquamous
carcinoma. Sarcomas and neuro-endocrine carcinomas are not eligible histologies.
2. Tumor progression or recurrence within 6 months of last dose of platinum therapy that
was used to treat metastatic, persistent or recurrent cervical cancer
3. Patient must have measurable disease as defined by RECIST 1.1.
4. Eastern Cooperative Oncology Group (ECOG) performance status ≤1
5. ≥18 years old
6. Adequate organ or bone marrow function
7. Received prior bevacizumab therapy or had clinically documented reason why not
administered
8. Received prior paclitaxel therapy or had clinically documented reason why not
administered
Key Exclusion Criteria:
1. Ongoing or recent (within 5 years) evidence of significant autoimmune disease that
required treatment with systemic immunosuppressive treatments
2. Prior treatment with an agent that blocks the PD-1/PD-L1 pathway
3. Prior treatment with systemic immune modulating agents (other than anti-PD-1/PD-L1
agents) that was within 28 days prior to enrollment, or within 90 days prior to
enrollment if there was an immune related adverse event, or associated with toxicity
that resulted in discontinuation of the immune modulating agent
4. Active or untreated brain metastases
5. Immunosuppressive corticosteroid doses (>10 mg prednisone daily or equivalent) within
4 weeks prior to the first dose of study drug (REGN2810 [cemiplimab] or IC chemo
6. Active infection requiring therapy
7. History of pneumonitis within the last 5 years
8. Documented allergic or acute hypersensitivity reaction attributed to antibody
treatments
9. Concurrent malignancy other than cervical cancer and/or history of malignancy other
than cervical cancer within 3 years of first planned dose of study drug (REGN2810
[cemiplimab] or IC chemo, except for tumors with negligible risk of metastasis or
death. Patients with hematologic malignancies (eg, chronic lymphocytic leukemia) are
excluded.
Note: Other protocol defined Inclusion/Exclusion may apply
We found this trial at
13
sites
Thomas Jefferson University Hospital Our hospitals in Center City Philadelphia share a 13-acre campus with...
Click here to add this to my saved trials
Univ of Washington Founded in 1861 by a private gift of 10 acres in what...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
220 Page Road North
Pinehurst, North Carolina 28374
Pinehurst, North Carolina 28374
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials